Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07657221 · ClinicalTrials.gov registry record · NA

Impact of Risk Feedback on Behavioral Trajectories

A NA study, sponsored by University of Southern California.

Not yet
Registry status
NA
Development phase
450
Enrollment target

NCT07657221: Clinical Trial NA study, sponsored by University of Southern California.

NCT07657221 is a NA study that has not yet begun recruiting, run by University of Southern California. The registered enrollment target is 450 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (68% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07657221, a NA study, has not yet begun recruiting, sponsored by University of Southern California.

NOT YET RECRUITING
Registry status
NA
Development phase
450 participants
Enrollment target

Study Summary

The goal of this study is to examine the effects of providing personalized information about behavioral, physical, and genetic factors that are associated with elevations in risk for some health problems. The main research question is: can we affect young adult behaviors through communication about these health-related risks? Participants will be asked to complete an in-person baseline session where they provide a DNA sample, complete online surveys, and do a brief interview. They will then receive one of several brief online information sessions and be followed in online surveys approximately every 3 months over the next 2 years.

Primary Outcome

Number of days consumed alcohol

Interventions

  • OTHER Control
  • BEHAVIORAL PHEN feedback
  • GENETIC PHEN+GENE Feedback

Trial Details

FieldValue
Enrollment Target 450 participants
Start Date 2026-08-18
Est. Completion 2030-08-31
Phase NA
University of Southern California

617 total trials

What is known before NCT07657221 opens enrollment

NCT07657221 is an interventional study that assigns participants to a tested intervention. The registered 450 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (68% lower).

The record links to 0 conditions, and to 3 interventions - of which Control is the first listed.

NCT07657221 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT07657221 about?

NCT07657221 is a clinical study titled "Impact of Risk Feedback on Behavioral Trajectories". The goal of this study is to examine the effects of providing personalized information about behavioral, physical, and genetic factors that are associated with elevations in risk for some health problems. The main research question is: can we affect young adult behaviors through communication about ...

What is the current status of trial NCT07657221?

This trial is currently not yet recruiting. It is a NA study. The enrollment target is 450 participants. The study started on 2026-08-18. Estimated completion is 2030-08-31.

What interventions are being tested in trial NCT07657221?

The interventions under investigation include: Control (OTHER), PHEN feedback (BEHAVIORAL), PHEN+GENE Feedback (GENETIC).

Who is sponsoring clinical trial NCT07657221?

This trial is sponsored by University of Southern California, which has 617 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT07657221's enrollment target sits among peer trials

450 225th of 2000 higher than 1,768 of 2,000 other NA trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00515060 · 450 participants

    Psychophysical Studies of Cancer Therapy Pain

  • NCT01257269 · 450 participants

    Genotype and Phenotype Correlation in Hereditary Thrombotic Thrombocytopenic Purpura (Upshaw-Schulman Syndrome)

  • NCT03047161 · 450 participants

    Electrophysiology of Fetal Arrhythmia

  • NCT03269630 · 450 participants

    New Orleans Pulmonary Hypertension Biobank

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT07657221, the US trial registry maintained by the National Library of Medicine. NCT07657221 (mid enrollment · none site footprint · not yet recruiting) retrieved and formatted by PlainTrial, see methodology.